HCW Biologics Profit Margin

The latest profit margin for HCWB is -437.65% as of June 2026. That compares with -2588.0% in the prior-year period — up 83.1% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside HCW Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HCWB's profit margin moved from -2588.0% to -437.65% — a 83.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in HCW Biologics's valuation or profitability profile.

Against Healthcare companies, HCWB currently prints -437.65% for profit margin, while the sector average sits near 13.76%. That is roughly 3280.5% below the sector mean. Large gaps often invite a closer look at HCW Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively HCW Biologics converts resources into returns. At -437.65%, HCWB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2588.0% in the prior-year period — up 83.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HCWB's profit margin (-437.65%), review year-over-year change from -2588.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.